Form 4: Johnson & Johnson Executive Sells Over 19,000 Shares in Pre-Planned Transaction

John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, sold 19,137 shares of common stock for approximately $163.55 per share under a Rule 10b5-1 plan.

Summary

• John C. Reed, Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson (JNJ), reported a sale of common stock.
• The transaction involved the disposition of 19,137 shares of JNJ common stock.
• The shares were sold at a weighted average price of $163.5486 per share, with prices ranging from $163.52 to $163.61.
• The sale occurred on July 17, 2025, and was filed on July 18, 2025.
• Following this transaction, John C. Reed directly beneficially owns 10,658 shares of Johnson & Johnson common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: Neutral. The sale is a routine insider transaction executed under a pre-planned Rule 10b5-1 plan, which mitigates negative interpretations often associated with insider sales.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, which indicates a pre-scheduled sale rather than a reaction to new, non-public information, potentially reducing negative market interpretation.

Negatives

• An executive selling a significant number of shares (19,137 shares) could be perceived negatively by some investors, even if pre-planned.

Risks

• Potential for negative market perception if investors misinterpret the Rule 10b5-1 sale as a lack of confidence, despite its pre-planned nature.

Future Outlook

The document does not provide forward-looking statements or guidance regarding Johnson & Johnson's future performance or strategic outlook.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer, or a security holder.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader insights into industry trends or competitive landscape beyond the specific company.

Comparison to Industry Standards

• This document is a standard insider trading report (Form 4) and does not contain information suitable for comparison to industry-specific financial or operational benchmarks. It details a personal stock transaction by an executive, not company performance.

Stakeholder Impact

• Shareholders: May observe a reduction in executive ownership, though mitigated by the 10b5-1 plan.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report.

Key Dates

Keywords

Johnson & Johnson, JNJ, SEC Form 4, Insider Trading, Stock Sale, Executive Compensation, Rule 10b5-1, Common Stock, John C. Reed